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Friedreich’s Ataxia: A Comprehensive Overview 
  
The intent of this presentation is to provide a comprehensive review of Friedreich’s 
ataxia, including its etiology, pathophysiology, diagnostic signs, and potential treatments for 
speech-language pathologists to use in their clinical practice.  
Friedreich’s ataxia (FRDA) is a chronic, progressive disorder that affects multiple 
systems within the body, including the central nervous system (CNS) and the peripheral nervous 
system (PNS). The disorder was founded and named after Nikolaus Friedreich, who was a 
German physician in the late 1800s. Friedreich’s ataxia is an inherited recessive disorder caused 
by a mutation of the homozygous triplet GAA expansion in the FXN gene on chromosome 9q13, 
which is responsible for producing the frataxin protein; a protein that is involved in iron 
metabolism and neuronal mitochondrial execution. The disorder affects approximately 1 in every 
50,000 people that reside in the United States and is considered the most common form of 
recessive ataxia in the U.S. and Europe. Primary characteristics of the disorder include 
incoordination of movement, dysarthria, and gait and limb apraxia.  
 Friedreich’s ataxia is characterized by a decrease in size of the dorsal root ganglia in 
addition to degeneration in the dorsal spinocerebellar tract and the lateral corticospinal tract. 
Severe degeneration is also found in the dentate nucleus located within the cerebellum, 
ultimately causing atrophy of the superior cerebellar peduncle. The neuropathophysiology results 
in ataxic dysarthria, altered nasality, voice quality, respiration, articulation, and phonation. Non-
speech symptoms include uncoordinated gait, inability to balance or coordinate movements, 
weakness in the legs, sensory loss, and scoliosis. Other symptoms associated with Friedreich’s 
ataxia are hearing loss, diabetes, dysphagia, dysmetria, chewing difficulty, abnormal eye 
movements, and loss of vision, which are likely the result of extensive degeneration of associated 
structures. At this point in time, there is no cure for Friedreich’s ataxia and no known treatment 
that reduces the progression of the disorder. Medical treatment includes pharmacological usage, 
with an emphasis on antioxidants, though there have not been significant findings on the 
effectiveness of these treatments.  
The role of the speech-language pathologist is to treat motor speech disorders that occur 
in individuals with Friedreich’s ataxia in addition to providing therapy for dysphagia. Treatment 
is primarily behavioral and efforts are focused on problems related to motor control and 
coordination, which interfere with systems responsible for speech rate and prosody.  This 
presentation will provide a comprehensive overview of Friedreich’s ataxia, and provide speech-
language pathologists with evidence-based treatment approaches. 
 
